A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Abstract
Abstract Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications. This review offers a comprehensive clinical overview of PARP inhibitor approvals, emphasizing their efficacy across different cancers based on landmark phase 3 clinical trials.
Article Details
Authors (11)
Chadi Hage Chehade
Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
Georges Gebrael
Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
Nicolas Sayegh
Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
Zeynep Irem Ozay
Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
Arshit Narang
Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
Tony Crispino
UsTOO Prostate Cancer Support and Education Las Vegas Chapter Las Vegas Nevada USA
Talia Golan
Division of Medical Oncology Sheba Medical Center Tel Aviv Medical University Tel Aviv Israel
Jennifer K. Litton
Division of Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
Umang Swami
Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
Kathleen N. Moore
Division of Gynecologic Oncology Stephenson Cancer Center University of Oklahoma Oklahoma City Oklahoma USA
Neeraj Agarwal
Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA